Modality
ADC
MOA
BiTE
Target
AuroraA
Pathway
NF-κB
MM
Development Pipeline
Preclinical
~Oct 2013
→ ~Jan 2015
Phase 1
~Apr 2015
→ ~Jul 2016
Phase 2
~Oct 2016
→ ~Jan 2018
Phase 3
~Apr 2018
→ ~Jul 2019
NDA/BLA
Oct 2019
→ Sep 2027
NDA/BLACurrent
NCT06738282
209 pts·MM
2019-11→2026-10·Completed
NCT06167745
518 pts·MM
2019-10→2027-09·Terminated
727 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-11-025mo agoPh1 Dose Esc· MM
2026-10-237mo awayPh3 Readout· MM
2027-09-011.4y awayPh3 Readout· MM
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Termina…
NDA/BLA
Complet…
Catalysts
Ph1 Dose Esc
2025-11-02 · 5mo ago
MM
Ph3 Readout
2026-10-23 · 7mo away
MM
Ph3 Readout
2027-09-01 · 1.4y away
MM
CompletedTerminated|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ |